Lantheus Holdings, Inc. (LNTH)

76,15 +8,76 (+13,01%) In data: 02:33PM EDT. Mercato aperto.

Lantheus Holdings, Inc.

201 Burlington Road
South Building
Bedford, MA 01730
United States
978 671 8001
https://www.lantheus.com

Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno: 834

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Brian A. Markison	CEO & Director	139,19k	N/D	1959
Mr. Paul M. Blanchfield	President	1,18M	N/D	1982
Mr. Robert J. Marshall Jr., CFA	CFO & Treasurer	1,3M	N/D	1967
Mr. Daniel M. Niedzwiecki	Chief Administrative Officer, General Counsel & Corporate Secretary	920,09k	133,82k	1978
Dr. Jean-Claude Provost M.D.	Chief Medical Officer	901,8k	N/D	N/D
Ms. Andrea Sabens	Chief Accounting Officer	N/D	N/D	1979
Ms. Dorothy Barr	Senior Vice President of Manufacturing & Technical Operations	N/D	N/D	N/D
Mr. Mark Richard Kinarney	Senior Director of Investor Relations	N/D	N/D	N/D
Ms. Linda S. Lennox	VP of Corporate Communications & Chief of Staff	N/D	N/D	1966
Ms. Carol Walker	Senior Vice President of Quality	N/D	N/D	1963

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Lantheus Holdings, Inc. al 1 maggio 2024 è 4. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 7; diritti degli azionisti: 2; retribuzione: 2.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.